Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2021-02-19
Target enrollment:
Participant gender:
Summary
The purpose of this randomized controlled Phase II study is to assess the efficacy of PDR001
versus investigator's choice of chemotherapy in patients with advanced NPC.
By blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2, PDR001 leads to the
activation of a T cell mediated antitumor immune response